SIRTURO® Is the First Medication for Pulmonary MDR-TB With a Novel Mechanism of Action in Over 40 Years

Mechanism of Action

  • SIRTURO® is the first anti-TB drug to interfere with bacterial energy metabolism.
    • SIRTURO® specifically inhibits mycobacterial ATP (adenosine 5'-triphosphate) synthase, by binding to subunit c of the enzyme that is essential for the generation of energy in Mycobacterium tuberculosis.

Download a comprehensive resource on SIRTURO® (bedaquiline) tablets